Randomised Clinical Trial: The Efficacy and Safety of Oltipraz, a Liver X Receptor Alpha-Inhibitory Dithiolethione in Patients With Non-Alcoholic Fatty Liver Disease

Alimentary Pharmacology and Therapeutics - United Kingdom
doi 10.1111/apt.13981
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Letter: The Efficacy of Oltipraz in Patients With Non-Alcoholic Fatty Liver Disease Has Not Been Confirmed

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Letter: The Efficacy of Oltipraz in Patients With Non-Alcoholic Fatty Liver Disease Has Not Been Confirmed-Authors’ Reply

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Efficacy and Safety of Phytosomal Curcumin in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial

Drug Research
MedicineDrug Discovery
2017English

Synbiotic Supplementation in Lean Patients With Non-Alcoholic Fatty Liver Disease: A Pilot, Randomised, Double-Blind, Placebo-Controlled, Clinical Trial

British Journal of Nutrition
MedicineNutritionDietetics
2017English

Differences in the Genetic Backgrounds of Patients With Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease

JGH Open
HepatologyGastroenterology
2018English

Editorial: Liver Transplantation in Patients With Non-Alcoholic Fatty Liver Disease and Obesity

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Expression of Resistin in the Liver of Patients With Non-Alcoholic Fatty Liver Disease

Polish Journal of Pathology
MedicineForensic MedicinePathology
2017English

Fructose Intake in Patients With Non-Alcoholic Fatty Liver Disease

Proceedings of Singapore Healthcare
Medicine
2019English

Epicardial Fat in Patients With Non-Alcoholic Fatty Liver Disease

Journal of Hepatology
Hepatology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy